IP Verse

Crystalline Forms Of A Prolyl Hydroxylase Inhibitor

Patent No. EP3470397 (titled "Crystalline Forms Of A Prolyl Hydroxylase Inhibitor") was filed by Fibrogen on Jul 15, 2013. The application was issued on Dec 29, 2021.

Patent Summary

Crystalline forms of the drug compound [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound A) for treating conditions associated with hypoxia, anemia, and ischemia. The disclosure provides specific crystal structures of Compound A and salts, as well as amorphous forms. These crystalline forms can be used to make pharmaceuticals for treating conditions like anemia, ischemia, and hypoxia disorders.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKSep 29, 2022ELKINGTON AND FIFE
SANDOZSep 28, 2022TER MEER STEINMEISTER & PARTNER
TEVA PHARMACEUTICALSSep 28, 2022D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3470397

FIBROGEN
Application Number
EP18189607A
Filing Date
Jul 15, 2013
Status
Granted And Under Opposition
Nov 26, 2021
Publication Date
Dec 29, 2021
External Links
Slate, Register , Google Patents